KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Income: 2017-2025

Historic Net Income for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$15.4 million.

  • Aquestive Therapeutics' Net Income fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.00%. This contributed to the annual value of -$44.1 million for FY2024, which is 460.83% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Net Income of -$15.4 million as of Q3 2025, which was down 14.01% from -$13.5 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Net Income registered a high of $8.1 million during Q1 2023, and its lowest value of -$28.9 million during Q4 2021.
  • Its 3-year average for Net Income is -$9.4 million, with a median of -$11.5 million in 2024.
  • In the last 5 years, Aquestive Therapeutics' Net Income soared by 161.03% in 2023 and then crashed by 465.55% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Net Income (Quarterly) stood at -$28.9 million in 2021, then spiked by 57.33% to -$12.4 million in 2022, then surged by 34.33% to -$8.1 million in 2023, then plummeted by 110.27% to -$17.1 million in 2024, then crashed by 34.21% to -$15.4 million in 2025.
  • Its Net Income was -$15.4 million in Q3 2025, compared to -$13.5 million in Q2 2025 and -$22.9 million in Q1 2025.